Last reviewed · How we verify
Placebo for DCCR — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo for DCCR (Placebo for DCCR) — Soleno Therapeutics, Inc.. This drug is a placebo for DCCR, meaning it has no active therapeutic effect.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo for DCCR TARGET | Placebo for DCCR | Soleno Therapeutics, Inc. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo for DCCR CI watch — RSS
- Placebo for DCCR CI watch — Atom
- Placebo for DCCR CI watch — JSON
- Placebo for DCCR alone — RSS
Cite this brief
Drug Landscape (2026). Placebo for DCCR — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-for-dccr. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing